Federal Register / Vol. 65, No. 125 / Wednesday, June 28, 2000 / Notices 39915

pharmaceuticals dispensed by each

program. DSS/HRSA will continue to

compile summary reports that are

distributed back to grantees and State

ADAPs on a quarterly basis. HRSA, the

Department of Health and Human

Services and the Office of Management

and Budget also utilize these summary

reports. The data collected are used to

guide program planning, formulate

budget recommendations, and monitor

State ADAPs, especially monitoring the

balance between an individual State

ADAP’s available resources against the

client demand for medications. The

burden estimates are as follows:

HRSA form Number of

respondents

Reponses

per

respondent

Total

responses

Hours per

responses

Total

burden

hours

Title II ADAP Grantees (Clients and Expenditures) ................................ 54 12 648 0.75 486

Title II ADAP Grantees (Pricing) .............................................................. 54 4 216 0.75 162

Total .................................................................................................. 54 16 864 0.75 648

Send comments to Susan G. Queen,

HRSA Reports Clearance Officer, Room

14–33, Parklawn Building, 5600 Fishers

Lane, Rockville, MD 20857. Written

comments should be received on or

before August 28, 2000.

Dated: June 21, 2000.

Jane Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 00–16257 Filed 6–27–00; 8:45 am]

BILLING CODE 4160–15–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

High-Speed Interlaced Spin Echo

Magnetic Resonance Imaging

Jeff Duyn (CC)

DHHS Reference No. E–171–99/0 filed

30 Dec 1999

Licensing Contact: Carol Salata; 301/

496–7735 ext. 232; e-mail:

cs253n@nih.gov

Spin-echo acquisition in magnetic

resonance imaging (MRI) facilitates the

observation of anatomical abnormalities

in pathologies such as brain tumors,

stroke and multiple sclerosis. It can also

be applied in conjunction with

perfusion techniques for the

investigation of function, based on

susceptibility contrast agents as well as

blood oxygen level dependent (BOLD)

contrast. Improving the efficiency of

spin echo MRI is the subject of the

current invention. It provides a method

of reducing scan time in multi-slice

spin-echo MRI through effective use of

the echo delay time between radio

frequency (RF) excitation and reception.

This technique has been evaluated in

examples of brain scans and has

indications that a substantial increase in

scan speed can be achieved without loss

in image signal-to-noise ratio or

contrast.

Laparoscopic Sac Holder Assembly

McClellan M. Walther, Frank Harrington

(NCI)

Serial No. 09/368,824 filed 05 Aug 1999

Licensing Contact: John Peter Kim; 301/

496–7056 ext. 264; e-mail:

jk141n@nih.gov

The present application describes a

device and method for accessing and

retrieving tissue from a body cavity

through minimally invasive endoscopic

procedures. Specifically, the present

invention consists of a sac holding

device, having a rotatable hinge joining

bowed leaf elements. The bowed leaf

elements form a loop which is adapted

to open and close the sac by rotation of

the bowed leaf elements. With this

laparoscopic device, one can easily

contain materials that have been

targeted for removal from body cavities.

Pieces of infected or cancerous tissue

and body fluids are easily contained and

can be removed without the danger of

collateral contamination.

Novel Diagnostic Standards for Virus

Detection and Quantification

Richard Y. Wang and James W. Shih

(CC)

DHHS Reference Nos. E–228–98/0 filed

20 Apr 1999 and E–228–98/1 filed 20

Apr 2000

Licensing Contact: John Peter Kim; 301/

496–7056 ext. 264; e-mail:

jk141n@nih.gov

The gene amplification is a tool for

the detection of trace amounts of

nucleic acids and the clinical

applications of this technique in

diagnosis of human diseases have been

widely demonstrated. There are

numerous steps from sample

preparation to final product analysis for

gene amplification-based molecular

diagnosis of clinical specimens. Small

variations in each step among different

samples can have profound impacts on

the final results.

There is a need for stable and wellcalibrated internal standards to enable

to monitor every step of the

amplification process, e.g., sample

preparation, gene amplification, and

amplicon detection. The subject

invention is directed to internal

standards as recombinant viral particles.

The particles contain modified target

sequence and multiple targets can also

be packaged. Particles containing RNA

target sequence of human hepatitis C

virus (HCV) were constructed as

example. Thus, this approach in making

internal standards has commercial

potential in molecular testing for

clinical diagnosis, blood screening, and

process validation.

39916 Federal Register / Vol. 65, No. 125 / Wednesday, June 28, 2000 / Notices

Dated: June 15, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–16325 Filed 6–27–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Gene Profiling Arrays

Ena Wang, Lance Miller, Francesco

Marincola (NCI)

DHHS Reference No. E–086–00/0 filed

28 Mar 2000

Licensing Contact: Richard Rodriguez;

301/496–7056 ext. 287; e-mail:

rr154z@nih.gov

The invention(s) embodied in this

application, provides for ordered arrays

of mixtures of nucleic acid molecules,

which reflect the gene expression

profile of one or more specimens, such

as different cell types or tissues. In

particular embodiments, complete

mRNA mixtures (i.e. gene transcripts) or

cDNA representatives from specimens

are individually arrayed on a substrate.

Such mixtures of nucleic acids can be

derived from any specimen source,

including animal, plant and/or

microbial cells and can be assembled in

any collection desired. The collections

can, for instance, include nucleic acid

mixtures from different cell types,

different phenotypes, cells grown under

different conditions, cells of different

ages or developmental stages, and so

forth. The nucleic acid arrays are

provided in both macro- and microformats and are suitable for measuring

the relative abundance of particular

gene transcripts across a collection of

complex nucleic acid mixtures.

Techniques are also disclosed for

producing high-fidelity, amplified

mixtures of nucleic acid molecules

using a combination of RNA (sense or

anti-sense) amplification and templateswitching synthesis. Amplified mixtures

produced using this method can, for

instance, be applied to the disclosed

arrays. The disclosed arrays allow high

throughput analysis of differential gene

expression in a specimen, such as a

tumor, or a variety of specimens, such

as a variety of tumors, and is suitable for

automated preparation and analysis.

The Isolation of a New Gene, TRAG,

Associated with TGF–Beta

Snorri S. Thorgeirsson, Sean R. Sanders

(NCI)

DHHS Ref. No. E–047–00/0 filed 07 Mar

2000 and 60/187,848 filed 08 Mar

2000

Licensing Contact: Susan S. Rucker;

301/406–7056 ext. 245; e-mail:

sr156v@nih.gov

A new gene has been isolated from a

cell line resistant to a protein, TGF-beta,

which can block the proliferation of

cancer cells. This resistance endows the

cell with cancer forming abilities. The

protein encoded by the newlydiscovered TRAG gene has been found

at much higher levels in these cancerforming cells than their non-cancerous

ancestors. In addition, the TRAG protein

is greatly elevated in many other rodent

and human cancer cell lines and in

primary mouse liver tumors, but not in

surrounding non-tumorous tissue. This

indicates a strong association between

TRAG and cancer-forming potential.

TRAG may be involved in the

mechanism by which normal cells

become cancerous. The TRAG gene

could provide an excellent target for

cancer or gene therapy. Abrogation of

TRAG protein production using antisense oligonucleotides or antibodies

could conceivably prevent, reduce, or

destroy certain types of tumors.

Identification of a Novel Domain in the

Tumor Necrosis Factor Receptor Ligand

Family that Mediates Pre-Ligand

Receptor Assembly and Function

MJ Lenardo, FK Chan, R Siegel (all of

NIAID)

Serial No. 60/181,909 filed 11 Feb 2000

Licensing Contact: Susan S. Rucker;

301/496–7056 ext. 245; e-mail:

sr156v@nih.gov

This application discloses the

identification of a functional domain,

which is essential for signaling

involving receptors of the Tumor

Necrosis Factor Superfamily (TFNR’s)

including TNFR–1 (p60), TNFR–2 (p80),

Fas, TRAIL–R, LTβR, CD40, CD30,

CD27, HVEM, OX40 and DR4. The

functional domain, denoted the PreLigand Assembly Domain (PLAD), can

be isolated as functional polypeptides

which can be useful in inhibiting the

first step in TNFR mediated signaling,

ligand-independent assembly of

members of the TNFR Superfamily. The

ability to inhibit TNFR signaling

suggests that these PLAD polypeptides

may be useful in developing new

therapeutic molecules or as therapeutic

molecules themselves for modulation of

immune responses, apoptosis, and

inflammation.

In addition to being available for

license, the investigators who have

developed this technology are also

willing to consider entering into a

CRADA relationship with companies

interested in commercial development

of this technology.

Transition Metal Complexes of N,N′,N′′-

trialkyl-cis,cis-1,3,5-

triaminocyclohexane and Related

Compositions and Methods

Martin W Brechbiel, Roy P. Planalp,

Kim A. Deal (NCI)

DHHS Reference No. E–072–99/0 filed

10 Aug 1999

Licensing Specialist: Girish C. Barua;

301/496–7735 ext. 263; gb18t@nih.gov

The invention is directed to copper

complexes of N,N′,N′′-trimethyl-cis,cis1,3,5-triaminocyclohexane and N,N′,N′′-

triethyl-cis,cis-1,3,5-

triaminocyclohexane as well as methods

of producing and using said complexes.

These complexes are capable of cleaving

DNA and RNA in vitro and could be

used for the treatment of cancer or other

disease states that are characterized by

abnormal cellular proliferation. The

complexes could also be used as

delivery agents or as imaging-tracers.

These complexes offer advantages over

previously described cleaving

methodologies, e.g., oxidative or

transesterification protocols. The

disclosed copper-complexes act via

hydrolytic reactions. These advantages

could offer significant benefits over

related therapeutic approaches to the

aforementioned abnormal conditions.